The efficacy of vildagliptin monotherapy was also
established in an Asian population. In a 24-week monotherapy
study, vildagliptin 50 mg twice daily showed efficacy
comparable with that of acarbose administered up to 100 mg
three times daily in Chinese patients (−1.4% versus −1.3%
from a baseline of 8.6%; statistical noninferiority established)
and was associated with significantly better gastrointestinal
tolerability than was the alpha-glucosidase inhibitor